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Summary 
 
Significant advances have been achieved in the understanding of the 
pathogenesis of inflammatory bowel disease (IBD). A number of susceptibility genes 
have been detected by large genome wide screening-approaches. New therapeutic 
concepts emerge from these insights. The most important progress in recent years 
certainly is the introduction of biologics in the therapy of IBD.  
 
TNF blockers have been shown to be very effective for the control of 
complicated disease courses. Currently, in addition to the three already established 
anti-TNF antibodies, new anti-TNF molecules, for example Golimumab, are in clinical 
trials and also reveal promising results. However, not all of the patients respond to 
anti-TNF treatment and many patients lose their response. Therefore, additional 
therapeutic approaches are urgently needed. Attractive therapy targets are cytokines 
as well as their receptors and signaling pathways. At the moment a large number of 
biologicals and inhibitors are tested in clinical trials and some of them provide very 
promising results for the treatment of IBD patients. In particular, inhibition of IL-
12p40 by specific antibodies as well as of the janus kinase (JAK)3 by a small mole-
cule promise to be very effective approaches. Though antibodies targeting for exam-
ple IL-6, IL-6R, IL-13 or CCR9 are only in the early steps of clinical development, 
they have already demonstrated to be a possible treatment option which needs to be 
confirmed in further trials.  
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Taken together a large number of new therapeutic anti-cytokine ap-
proaches are currently tested in clinical trials in IBD patients. In this review, the new 
therapeutic approaches for cytokine inhibition in IBD patients are discussed. 
 
Keywords: Anti-cytokine antibodies, biologicals, Crohn’s disease, cytokines, inflam-
matory bowel disease, ulcerative colitis,  
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Introduction 
Inflammatory bowel disease (IBD) represents a chronic intestinal inflam-
mation and is comprised of its two major forms, Crohn’s disease (CD) and ulcerative 
colitis (UC). The pathogenesis of IBD involves a complex interplay between genetic 
susceptibility of the host, external environmental factors, the internal intestinal mi-
crobiota, infectious particles and a dysregulated immune system. Current hypothesis 
suggests that an epithelial barrier defect in a genetically susceptible host results in 
an aberrant immune response to environmental and “in-vironmental” factors[1, 2]. In 
particular, the aberrant immune response involves both, the innate as well as the 
adaptive immune system providing a large number of pro- and anti-inflammatory cy-
tokines as possible causative as well as disease-promoting molecules in IBD patho-
genesis. Being involved in intestinal inflammation these cytokines have been selected 
as treatment targets. A further and also a very promising approach seem to be anti-
adhesion molecule strategies, for example α4β7-integrin inhibitors, such as Vedoli-
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zumab. However, as this review was intended to focus on anti-cytokine therapies 
those promising anti-adhesion approaches are not further featured in this review. 
Cytokines are produced by lymphocytes (especially by T-cells of the Th1, 
Th2 and Th17 phenotype), monocytes, intestinal macrophages, granulocytes, epithe-
lial cells, endothelial cells, and fibroblasts. They have pro-inflammatory (interleukin 
(IL)-1, tumor necrosis factor (TNF), IL-6, IL-8 or IL-12) and/or anti-inflammatory (IL-
1 receptor antagonist [IL-1ra], IL-4, IL-10, IL-11 or transforming growth factor ß 
[TGFß]) functions.  
Mucosal and systemic concentrations of many pro- and anti-inflammatory 
cytokines are elevated in IBD patients[3]. For example, an imbalance between pro-
inflammatory and anti-inflammatory cytokines was found for the IL-1/IL-1ra ratio in 
the inflamed mucosa of patients with CD, UC, diverticulitis and infectious colitis[4]. 
Furthermore, inhibition of pro-inflammatory cytokines or supplementations with anti-
inflammatory cytokines reduced inflammation in animal models of colitis, such as the 
dextran-sulfate sodium (DSS) colitis model, the trinitrobenzene sulfonic acid (TNBS) 
model or the genetically engineered IL-10 knock-out colitis model[5, 6, 7, 8, 9]. 
To obtain a complete as possible overview of all of the current strategies 
to target cytokines and cytokine-related signaling, we performed a computerized sys-
temic search of English language publications in the PubMed, Cochrane Library, Eu-
ropean Medicines Agency and the Food and Drug Administration databases as well as 
current clinical trial databases (www.nih.gov and www.clinicaltrials.gov) until January 
2013. The following search terms were applied: “Crohn’s disease” or “inflammatory 
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bowel disease” or “ulcerative colitis” and “biologicals” or “biological” or “anti-cytokine 
therapy”.  
 
Cytokines as drug targets in IBD  
The inflammatory pattern in CD has been associated with enhanced oc-
currence of T-helper (Th)1 and Th17 cells, while the T-cell signature of UC is more 
similar to a Th2 cell disease type[1, 10]. The development of Th1 and Th17 cells in 
CD is triggered by inflammatory mediators, such as IL-12, IL-18, IL-23 and TGFβ 
that are secreted by antigen presenting cells (APC) and macrophages[11]. Presence 
of these Th-cell subsets results in elevated levels of the pro-inflammatory cytokines 
IL-2, IL-17, TNF and IFNγ in the serum as well as in the intestinal mucosa of CD pa-
tients, what finally causes secretion of TNF, IL-1β, IL-6, IL-8, IL-12 and IL-18 from 
APC, macrophages, fibroblasts, endothelial and epithelial cells. These events promote 
ongoing inflammation and finally establish the secretion of pro-inflammatory cyto-
kines as a vicious circle[12, 13, 14, 15]. As mentioned, mucosal inflammation in UC 
has a pattern of cytokine secretion that is similar to the pattern secreted by the Th2 
cell-type including increased levels of IL-4, IL-5 and IL-13[16]. Vice versa IL-4, IL-5 
and IL-13 promote Th2 cell differentiation which further may augment levels of IL-
13[16, 17]. T-cells can also be directly activated via antigen presentation by APC. An-
ti-inflammatory cytokines, such as IL-10, are also important in modulating T-cell ac-
tivity. 
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 Based on these findings the rationale for cytokine-modulating treatment 
of IBD patients was defined (Figure 1). Different strategies like the inhibition of pro-
inflammatory cytokines or the administration of anti-inflammatory cytokines led to 
some promising results. In general there are three different mechanism of anti-
cytokine treatment possible: First, an antibody or inhibitor that targets the cytokine 
directly. Secondly, an antibody or inhibitor of the respective cytokine receptor and 
thirdly, a molecule that inhibits signaling pathways that are crucial for mediating cy-
tokine-induced effects by targeting intracellular signaling molecules. Thirdly, the ad-
ministration of anti-inflammatory cytokine seems to be a promising approach. How-
ever, so far, only two cytokines, namely TNF and the p40 subunit of IL-12/IL-23, 
have been proven to be successful targets for treating IBD patients. To date, anti-
TNF antibodies are the only anti-cytokine antibodies that have been approved in IBD. 
Additionally, ustekinumab an antibody targeting the p40 subunit of IL-12/IL-23 is 
currently about to be approved for treatment of CD after excellent results in clinical 
phase IIb trials. For example, in contrast to anti-TNF treatment, targeting of IFNγ us-
ing the antibody fontolizumab finally failed in placebo-controlled clinical studies to 
show a significant clinical benefit in CD patients[18, 19, 20]. 
 
There are a large number of studies ongoing investigating a possible 
beneficial effect of anti-cytokine treatment in IBD patients, such as therapies target-
ing TNF, IL-6, IL-6 receptor (IL-6R), IL-12, IL-23, IL-17A, IL-18,  anti-C-C chemokine 
receptor type 9 (CCR9) or anti-C-X-C motif chemokine 10 (CXCL10) (Table 1). The 
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respective medications are either biological agents or small molecule inhibitors. 
Though biological medications feature some advantages, such as potency of action 
and specificity, what might reduce their off-target side effects, they also exert certain 
disadvantages, such as immunogenicity, high costs or a long half-life, what might re-
sult in prolonged immunosuppression and infectious complications. Further, though 
treatment with anti-TNF antibodies is successful in a certain number of patients, only 
up to 50 % achieve steroid free remission and some of them will even lose their re-
sponse after a certain period of time[21, 22, 23]. Therefore, it is obvious that new 
therapeutic strategies targeting cytokines in IBD need to be developed. 
 
New biologicals directed against cytokines 
New anti-TNF strategies 
In 1997 the first successful study using an anti-cytokine approach was 
published showing the efficacy of the anti-TNF antibody, infliximab, in patients with 
CD[24]. In the meantime, two more anti-TNF antibodies have been approved for 
treatment of CD, namely adalimumab and certolizumab pegol. Further, infliximab and 
adalimumab are also approved for treatment of UC in the US and the EU.  However, 
not all of the tested anti-TNF approaches are effective. Namely the p75 TNF soluble 
receptor fusion protein etanercept[25], the IgG4 monoclonal anti-TNF antibody 
CDP571[26], the p55 TNF soluble receptor monomer onercept[27] or the small mole-
cule semapimod (CNI-1493)[28] failed in clinical trials.  For example, etanercept, a 
genetically engineered fusion protein consisting of two identical chains of the recom-
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binant human TNF-receptor (TNF-R) p75 monomer fused with the Fc domain of hu-
man immunoglobulin (Ig) G1 that binds and inactivates TNF, failed to show a clinical 
benefit in IBD patients[25]. In contrast, while etanercept is approved and very effi-
cient in the therapy of RA, thee observations demonstrate that results obtained in 
clinical trials with RA patients cannot be directly translated to IBD patients. Also, un-
fortunately up to 40% of CD patients do not have a sufficient response to anti-TNF 
treatment and are so-called “primary non-responders” and others develop antibodies 
against monoclonal antibodies leading to treatment modification and discontinuati-
on[21, 22, 23]. 
 
Golimumab 
Golimumab is a fully human monoclonal IgG-1 anti-TNF antibody under 
investigation for moderate to severe UC. The approved dose is 50mg subcutaneously 
once a month. It is licensed for the treatment of rheumatoid arthritis, psoriatic arthri-
tis and ankylosing spondylitis[29]. Results of the phase II/III PURSUIT trial, reported 
at Digestive Disease Week (DDW) 2012, showed significantly higher UC clinical re-
sponse and remission rates with this anti-TNF agent compared with placebo, im-
provements that were maintained throughout the 54-week study period[30]. In this 
large trial safety and efficacy was evaluated in moderately to severely active UC. All 
trial patients had failed to respond to or tolerate treatment with 6-mercaptopurine, 
azathioprine, corticosteroids or 5-aminosalicylates or were steroid dependent. Study 
patients were naïve to treatment with TNF-antibodies. The trial had an adaptive de-
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sign with Phase 2 dose ranging followed by a confirmatory phase 3 component. Pa-
tients were randomized to receive golimumab 100 mg/50 mg (prior to dose selection 
only), placebo or golimumab 200 mg/100 mg or 400 mg/200 mg at weeks 0 and 2. 
The primary endpoint was clinical response at week 6. Secondary endpoints at week 
6 included clinical remission, mucosal healing and a change from baseline in IBDQ 
scores. Overall, 1065 patients were treated in the study; 774 of these patients were 
randomized into the Phase 3 component of the study. Patients responding to induc-
tion treatment with golimumab were eligible to continue in the Phase 3 PURSUIT 
maintenance study. At week 6, a clinical response was observed in 45% to 57% of 
golimumab-treated patients (across dosing groups) compared with 31% of patients 
on placebo. A significant trend toward improved mucosal healing was also ob-
served. Adverse events in the golimumab groups included 1 death due to peritonitis, 
1 case of demyelination, and 1 colon cancer (detected in screening biopsies). No se-
rious infections were reported, and the safety profile was consistent with those of 
other anti-TNFs in inflammatory bowel disease (IBD) and of golimumab for rheuma-
tologic indications. Due to its subcutaneous application, efficacy and tolerability, go-
limumab might be an interesting option for outpatients suffering from moderate to 
severe colitis. 
 
TNF-Kinoid 
 An attractive alternative therapeutic strategy is active anti-TNF immuniza-
tion using TNF-Kinoid. TNF-Kinoid is a formulation in which human TNF is coupled to 
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keyhole limpet hemocyanin (KLH) as a carrier protein, inactivated and emulsified with 
MONTANIDE ISA 51 VG. It was developed by Neovacs SA; France. In a phase I-II 
dose escalation study it was administered intramuscularly on day 0,7 and 28 with a 
maintenance dose on day 168 in thirteen patients with moderate to severe Crohn’s 
disease[31]. Patient’s developed an anti-TNF antibody response that peaked within 
weeks and at week 4 and 12 36% and 54% of the patients demonstrated a clinical 
remission (CDAI<150) with a relevant decrease of calprotectin levels in stools. These 
promising results need further studies to confirm efficacy, safety and tolerability.   
 
 Ozoralizumab (ATN-103) 
Ozoralizumab (ATN-103) is a trivalent albumin-binding nanobody that 
neutralizes TNF. A nanobody is an antibody fragment (single domain antibody) that 
is, similar as a complete antibody, able to bind selectively to a specific antigen. ATN-
103 is currently in multi-center phase II trials against rheumatoid arthritis. It showed 
excellent safety and efficacy results in a 48-week phase II open-label study in rheu-
matoid arthritis patients who had insufficient response to methotrexate alone[32]. 
Ozoralizumab was administered by a subcutaneous injection every four weeks.  
 
DLX105 
DLX105 is a new type of an anti-TNF optimized single-chain Fv monoclo-
nal antibody which is developed for topical treatment in patients with chronic in-
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flammatory disorders, such as chronic skin inflammation, osteoarthritis and CD. The 
advantage is that DLX105 can be administered locally and presents hardly any sys-
temic resorption. A currently ongoing placebo-controlled phase I/IIa study analyses 
the efficacy of DLX105 when injected directly into the fistula tracts of CD patients.  
 
 Anti Interleukin-6 strategies 
Similar to TNF, the pleiotropic cytokine IL-6 also appears to play a pivotal 
role in the pathogenesis of IBD. IL-6 is produced by a large number of different cell 
types and secretion is induced during acute phase response. The major sources of 
IL-6 in the gut are macrophages whereas the results on secretion of IL-6 by epitheli-
al cells are conflicting. IL-6 exerts its physiological functions not only via its mem-
brane-bound IL-6 receptor (IL-6R), which is limited to a small number of cell types, 
such as hepatocytes or monocytes/macrophages, but also via its soluble IL-6 recep-
tor (sIL-6R). This way, IL-6 can signal to all body cells since the respective IL-6/sIL-
6R complex binds to the ubiquitously expressed receptor-subunit gp130[33, 34, 35]. 
IL-6 serum levels correlate with disease activity of both, CD and UC, and upon anti-
inflammatory treatment, IL-6 serum levels decline correlating to the decrease in dis-
ease activity[36, 37]. The induction of C-reactive protein (CRP) is the liver is mediat-
ed by IL-6. Also serum levels of sIL-6R are elevated in IBD patients and correlate 
with disease activity[38].  
Several studies also indicated a predictive value for IL-6 serum levels 
with respect to the detection of a CD relapse suggesting that IL-6 serum levels might 
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be a useful marker for disease monitoring. High IL-6 levels are associated with an in-
creased risk for relapse[39, 40]. Monitoring of IL-6 serum levels also reflects the clin-
ical response to steroid treatment and predicts clinical relapse after steroid-induced 
remission[41, 42]. Additionally, a polymorphism within the IL-6 gene locus has been 
associated with early onset CD and persistent activation of the IL-6 signaling path-
way is associated with the development of colorectal cancer[43, 44, 45, 46]. Due to 
these observations IL-6 is regarded to be a promising target for the treatment of 
IBD. 
Currently, the efficacy and safety of five biological therapies targeting IL-
6, namely sirukumab, olokizumab (CDP6038), C326, PF04236921 and BMS-945429, 
and one compound targeting IL-6R, namely tocilizumab, are investigated in clinical 
trials.  
 
Sirukumab 
Sirukumab (CNT0136) is an investigational human monoclonal IgG1 kap-
pa antibody targeting IL-6 which is currently in Phase III studies tested for the 
treatment of moderately to severely active rheumatoid arthritis (RA). A previous 
phase I study demonstrated that sirukumab exerts a well-tolerable safety profile, de-
sirable pharmacokinetic characteristics and a low incidence of immunogenicity follow-
ing an intravenous infusion in healthy subjects[47]. In phase II studies, sirukumab 
significantly improved RA signs and symptoms, as measured by the American College 
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of Rheumatology 50 (ACR50) response at week 12, the primary study endpoint, and 
treatment with sirukumab was generally well tolerated. 
 
Olokizumab 
A further highly potent anti–IL-6 monoclonal antibody, namely oloki-
zumab (CDP6038), selectively stops the final step in the IL-6 signaling complex as-
sembly. Several phase II trials of olokizumab were recently completed, but results 
have not yet been finally reported. The first evaluated CRP suppression with a single 
intravenous or subcutaneous dose of olokizumab in patients with active RA, despite 
therapy with MTX. The second evaluated the safety, efficacy, pharmacokinetics, and 
immunogenicity of various doses of olokizumab in comparison with placebo and also 
tocilizumab as add-on treatments to MTX in RA patients with an inadequate response 
to MTX and TNF inhibitors. This phase 2b study met its primary endpoint of demon-
strating a significant reduction in the disease activity score at week 12 across all olo-
kizumab dose groups relative to placebo. Still ongoing is a phase II, open-label, long-
term (up to 5 years) study of subcutaneous olokizumab in patients with active RA 
and inadequate response to MTX. Side effects reported in a phase I trial in healthy 
volunteers that were considered related to olokizumab included headache, reduced 
neutrophil and leukocyte counts, and small increases in ALT level. 
 
C326 
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A further approach to target IL-6 is C326, an Inhibitor of IL-6, which is 
currently investigated in a phase I study in adults with CD. C326 is a heterotetramer-
ic avimer (binding protein), which is composed of a fusion of the IgG binding domain 
to the N-terminus of the IL-6 binding trimer. By a placebo-controlled study design 
safety, pharmacokinetics, pharmacodynamics and immunogenicity of C326 will be 
assessed in CD patients.  
 
PF-04236921 
The fourth anti-IL-6 medication is called PF-04236921 which is a mono-
clonal, fully human IgG2 antibody targeting IL-6 and therefore inhibiting IL-6 induced 
signaling. It is currently under investigation in phase II trials in patients with CD, RA 
and systemic lupus erythematodes (SLE). Preclinical data and first observations in 
healthy volunteers as well as patients with RA demonstrated a good safety profile of 
PF-0426921. In particular, with respect to CD, there is a double-blind, randomized, 
placebo-controlled study ongoing that evaluates efficacy and safety of PF-04236921 
in CD patients who are non-responders to anti-TNF treatment (ANDANTE trial) as 
well as a phase II open label extension trial. Here, PF-04236921 will be tested as a 
possible treatment for the induction and maintenance of remission in patients with 
moderate to severe CD that have failed to response to anti-TNF therapy. 
 
BMS-945429 
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Additionally, BMS-945429 is a fully humanized monoclonal antibody tar-
geting free IL-6 and soluble IL-6R/IL-6 complex. In a phase IIa study in patients with 
moderate to severe RA, BMS-945429 was efficient to improve the signs and symp-
toms of RA as measured by ACR responses. Further, the agent was well tolerated.   
The efficacy of BMS-945429 is currently investigated in clinical phase II trials in pa-
tients with moderate to severe CD who had an insufficient response to conventional 
therapy or had failed anti-TNF treatment.  
    
 
 
Anti Interleukin-12/anti-Interleukin-23 strategies 
Recent genome wide association studies revealed that polymorphisms 
within the gene encoding IL-23 receptor (IL-23R) protect from CD[48]. IL-12 and IL-
23 consist of a dimer consisting of the common p40 subunit and of a unique subunit, 
namely p35 for IL-12 and p19 for IL-23. IL-12 and IL-23 are mainly produced by 
dendritic cells and are crucial for induction and maintenance Th1 (IL-12) and Th17 
(IL-23) responses[49]. Blocking IL-12 has been demonstrated to reduce the extent of 
TNBS-induced colitis in the mouse model and IL-23 seems to be the driving force for 
inflammation in a RAG-deficient mouse model of colitis[50, 51] making the IL-12/IL-
23 axis another promising target for the treatment of IBD. Several drugs inhibiting 
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the IL-12/IL-23 axis are currently under investigation, namely ustekinumab, briaki-
numab, apilimod mesylate, AMG139 and SCH-900222.  
 
Ustekinumab 
Ustekinumab is a fully human IgG1 monoclonal antibody targeting the 
p40 subunit of IL-12/IL-23 and is already approved for the treatment of moderate to 
severe plaque psoriasis. In a phase II trial including 104 patients with moderate to 
severe CD, clinical response rates to ustekinumab were significantly higher at weeks 
4 and 6 following treatment with ustekinumab than with placebo (53% vs. 30%). 
However, at the primary endpoint, week 8, these differences were no longer signifi-
cant (49% vs. 40%). Nevertheless, in the subgroup of patients that had previously 
failed to respond to anti-TNF therapy, week 8 response was significantly higher in 
patients receiving ustekinumab than in patients receiving placebo (59% vs. 
26%)[52]. A recent, larger randomized, placebo-controlled phase IIb trial investigat-
ed whether ustekinumab induces clinical response at week 6 as primary end point in 
a collective of 526 patients with moderate to severe CD who did not respond to in-
fliximab[53]. At week 6, a significantly higher number of patients treated with 
ustekinumab showed a clinical response compared to patients treated with placebo 
(39.7% vs. 23.5%). To those patients who responded to ustekinumab at week 6 
were given maintenance therapy. A significant number of these patients showed a 
clinical response (69.4% vs. 42.5%) and was in remission (41.7 vs. 27.4%) at week 
22 compared to patients receiving placebo[53]. This indicates that patients with TNF-
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refractory moderate to severe CD have a better response rate to ustekinumab. Fur-
ther, patients with an initial response to ustekinumab have significantly better rates 
of response and remission with ustekinumab used as maintenance therapy as com-
pared to control patients[53]. In general, ustekinumab was well tolerated. Therefore, 
ustekinumab seems to be a promising option in patients with TNF-refractory CD and 
additional phase III trials in patients with moderate to severe CD are ongoing. 
 
Briakinumab 
A further fully human monoclonal antibody to the p40 subunit of IL-12 
and IL-23 is called briakinumab. In a phase II trial in 79 patients with moderate to 
severe CD, briakinumab treatment resulted in clinical response in 75% of patients 
compared to 25% of patients treated with placebo. However this difference was no 
longer significant at week 18[54]. In a subsequent, larger phase II trial including 230 
patients with moderate to severe CD, the rates for clinical remission at week 6 and 
week 24 for briakinumab-treated patients were not significantly higher than those for 
patients treated with placebo[55]. An explanation for the different outcome of clinical 
trials using anti-IL-12/23 antibodies might be that ustekinumab and briakinumab dis-
play different binding capacities to the p40 subunit of IL-12/23. Further, the discrep-
ancy might be due to the fact that ustekinumab and briakinumba are immunologiclal-
ly rather different molecules. While ustekinumab is a fully human IgG1,κ antibody 
generated in human immunoglobulin transgenic mice, briakinumab is a recombinant 
exclusively human-sequence IgG1,λ monoclonal antibody isolated from human phage 
 19 
display library. These differences might, at least in part, explain the different trial 
outcomes of those two molecules. 
 
Apilimod mesylate 
Apilimod mesylate is an orally administered small molecule that inhibits 
the transcription of IL-12 and IL-23. An initial phase I/IIa trial in patients with mod-
erate to severe CD showed a clinical activity of the agent[56]. However, a following 
placebo-controlled, randomized phase II trial in 220 patients with moderate to severe 
CD revealed that apilimod mesylate has no significant effect on the induction of a 
clinical response at day 29 when compared to placebo. The trial was finally stopped 
by the Data Monitoring Committee[57].  
 
 
 
 
AMG139 
The safety and tolerability of AMG139, a human monoclonal antibody 
targeting the p19 subunit of IL-23 while sparing IL-12 and is currently investigated in 
phase I trials in patients with mild to severe CD.  
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SCH900222 
SCH900222 targets the p19 subunit of IL-23 and is currently under inves-
tigation in phase II/III trials in patients with plaque psoriasis.    
 
 
Anti Interleukin-13 strategies 
The Th2-related cytokine IL-13 is mainly produced by T-cells and natural 
killer cells (NK-cells). It seems to play a critical role for the development of UC, since 
it impairs epithelial barrier function and induces epithelial cell apoptosis. In the oxa-
lozone-induced mouse model of colitis, IL-13 is necessary for the development of in-
flammation and blockade of IL-13 ameliorates the extent of colitis. Further, lamina 
propria T-cells from UC patients produce clearly more IL-13 upon stimulation than 
those form CD patients[16, 58, 59, 60]. Inhibition of IL-13 production by administra-
tion of IFN-β1α in patients with UC ameliorated colitis[61]. These observations sug-
gest that IL-13 plays a pivotal role for the pathogenesis of UC and make it a plausible 
target for the treatment of UC. Interestingly, a recent study also demonstrated a sig-
nificant expression of IL-13 along the tracts of CD-associated fistulae and suggested 
an important role for IL-13 in the pathogenesis of CD-associated intestinal 
fistulae[62]. 
QAX576 
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Consequently, QAX576, a human monoclonal antibody targeting IL-13 is 
tested in a phase II study to assess its efficacy, safety and tolerability in the treat-
ment of perianal fistulas in CD patients.  
 
Anrukinzumab and tralokinumab 
Anrukinzumab, a humanized monoclonal antibody targeting IL-13, as well 
as tralokinumab (CAT-354), a recombinant human monoclonal antibody directed 
against IL-13, are currently tested in phase II studies in patients with moderate to 
severe UC.  
 
Lebrikizumab 
Additionally, the anti-IL-13 antibody lebrikizumab was successful in phase 
II studies in patients with severe asthma [63] and subsequent phase III studies are 
ongoing. 
 
 
Anti Interleukin-17 strategies 
IL-17, also called IL-17A, is the founding member of the IL-17 family of 
cytokines (IL-17A-F) and shares the highest homology with IL-17F. IL-17A is the sig-
nature cytokine of the recently defined Th17 cell population and is secreted by Th17 
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cells and innate lymphoid cells (ILCs). However, Th17 cells may also secrete IL-17F, 
IL-22 and/or IL-23 depending on the cellular context[64].  
Elevated levels of IL-17 have been observed in the inflamed intestinal 
mucosa of patients with CD and UC[65, 66]. Th17 cytokines seem to promote intes-
tinal inflammation by stimulating the secretion of pro-inflammatory cytokines, chem-
okines and tissue-degrading matrix metallo-proteinases finally resulting in tissue 
damage[67, 68, 69]. On the other hand, Th17-related cytokines have also been 
demonstrated to exert protective function in the intestine. These observations are 
supported by various mouse models of colitis. In example, chronic DSS-induced coli-
tis is aggravated in IL-17A knock-out animals, but ameliorated in IL-17F knock-out 
mice[70] and IL-17A exerts also a protective role in a T-cell transfer model of coli-
tis[71]. In contrast, in the TNBS-induced murine colitis model, colitis was ameliorated 
in IL-17 receptor A (IL-17RA) knock-out mice as well as in wild-type mice treated 
with an IL-17RA IgG1 fusion protein blocking signal transduction via the recep-
tor[15].  
The reason for these conflicting results is still unknown. However, it is 
assumed that the either protective or inflammatory role of Th17 cells in the intestine 
is dependent on the cytokine milieu during their differentiation and the co-expression 
of other cytokines, such as IL-10 or IFNγ[64]. Nevertheless, targeting IL-17 has been 
regarded to be a reasonable approach for the treatment of IBD.  
 
Vidolfludimus 
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 Vidofludimus, a small molecule inhibitor of the expression of both, IL-17A 
and IL-17F, has shown promising results in an open label, uncontrolled phase II trial 
including patients with either steroid-dependent UC or CD[72]. After administration 
of vidofludimus for 12 weeks to 26 steroid-dependent UC or CD patients, 8 out of 14 
CD patients (57.9%) and 6 out 12 UC patients (50%) were in steroid-free clinical 
remission (complete responders). 4 of 14 CD patients (28.6%) and 5 of 12 UC pa-
tients (41.7%) were partial responders, defined as being in remission at a steroid 
dose equal or lower than the individual patient's threshold dose for relapse. 2 CD and 
1 UC patient did not show any response. In general, vidofludimus was well tolerated. 
Though vidofludimus showed clinical efficacy and a good safety profile in this first 
IBD trial, further and more defined studies will be needed to obtain more meaningful 
data[72].  
  
Secukinumab 
 Secukinumab, a human monoclonal anti-IL-17A antibody, has shown 
promising results in patients with RA and psoriasis. However, a proof-of-concept 
study in 59 patients with moderate to severe CD failed and blockade of IL-17A was 
not only ineffective and associated with disease worsening, but also revealed higher 
rates of severe adverse events, mainly infections, compared to placebo[73].  
 
 Ixekizumab 
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 In addition to secukinumab, Ixekizumab (LY2439821), a humanized 
monoclonal antibody targeting IL-17A, is giving promising results and currently in a 
phase III study in patients with psoriasis and a phase II study in patients with RA. 
However, it remains to be determined whether it could become a therapeutic option 
in IBD patients. 
 
RG4934 
Further, RG4934, a monoclonal IL-17A antibody is currently in phase I/II 
studies in patients with psoriasis. 
 
 
Cytokines of the IL-1 family: Anti Interleukin-18 and anti-
Interleukin-1 beta strategies 
 The pro-inflammatory cytokines IL-1β and IL-18 are secreted via a 
unique intracellular protein complex, called the inflammasome. With respect to IBD, 
particularly the Nlrp3-inflammasome seems to play a crucial role for maintaining in-
testinal homeostasis and variations within the gene encoding Nlrp3 are associated 
with increased susceptibility to CD[74]. Nlrp3 protein provides a cytosolic platform for 
the assembling of the NALP3 inflammasome, a protein complex which is responsible 
for maturation and secretion of IL-1β and IL-18[75, 76, 77]. Both of the cytokines 
exert pro-inflammatory properties and are associated with epithelial repair and 
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wound healing by the recruitment and activation of immune cells and by the induc-
tion of pro-inflammatory cytokines, chemokines and growth factors. IL-1β levels in 
the colon correlated with disease activity and high levels of IL-1β protein are associ-
ated with active inflammatory lesions in IBD patients[78, 79]. Similar, serum levels of 
IL-18 are also elevated in UC and CD patients and protein expression of IL-18 has 
been shown to be increased in the intestine of CD patients[80, 81]. These early ob-
servations resulted in the assumption that IL-1β and IL-18 might contribute to the 
onset of IBD, especially since inhibition of IL-18 and IL-1β attenuated colitis in 
mouse models[82, 83, 84, 85, 86]. However, more recent studies suggested that IL-
18 and IL-1β exert an important anti-inflammatory role in the intestine, particularly 
by promoting tissue repair and restitution in of the ulcerated epithelium[87, 88, 89, 
90]. These observations are supported by IL-18, IL-18 receptor and IL-1receptor 
knock-out mice that are more susceptible to DSS-induced colitis than wild-type ani-
mals[91, 92]. Therefore, both cytokines were regarded to be potential targets for the 
treatment of IBD. 
 
Canakinumab 
Canakinumab is a high-affinity human monoclonal anti-IL-1β-antibody 
and is currently studied in phase I to III studies in patients with diseases such as 
acute gout[93], RA, juvenile rheumatoid arthritis or osteoarthritis.  
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XOMA 052 
A further anti-IL-1β antibody, XOMA 052 is currently in phase II studies 
in patients with RA and type II diabetes.  
 
GSK 1070806 
GSK 1070806 is a humanized monoclonal antibody targeting IL-18 which 
is currently studied in a phase I trial in healthy and obese subjects.  
 
 
 
 
Anti-IL-22 and anti-IL-5 strategies 
IL-22 is a further cytokine that is produced by Th17 cells and elevated 
levels of IL-22 have been observed in the intestinal mucosa of CD patients. Addition-
al data suggest that IL-22 is also produced by a different T-cell type, by some inves-
tigators called Th22 cells[94]. On a functional level, IL-22 increases proliferation and 
migration of intestinal epithelial cells and enhances the expression of pro-
inflammatory mediators, such as TNF-alpha or IL-8. Further, IL-22 is involved in reg-
ulating human defensin expression and mucus production[95]. However, recent stud-
ies also suggested a protective role for IL-22 in mouse models of colitis[96, 97]. 
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Fezakinumab, a monoclonal anti-IL-22 antibody has recently completed phase I and 
phase II studies for psoriasis and RA, respectively. It could be interesting to study, 
whether it might also an option for the treatment IBD patients. 
 
IL-5 is regarded to be a Th2 cytokine and isolated lamina propria mono-
nuclear cells from UC patients produce more IL-5 than those of control and CD pa-
tients upon stimulation[16, 98, 99]. In the oxazolone-induced colitis mouse model, 
which is a model of close to human UC, increased levels of IL-5 are one of the driv-
ing forces of the disease suggesting IL-5 could also be a target for treatment of IBD, 
particularly UC. Mepolizumab and Reslizumab are humanized monoclonal anti-IL-5 
antibodies which are currently in phase III studies in patients with asthma and eo-
sinophilic esophagitis. 
 
 
Anti- C-X-C motif chemokine 10 (CXCL10) strategies 
CXCL10, which is also known as interferon inducible 10-kd protein (IP-
10), is secreted by various cell types, such as monocytes, endothelial cells and fibro-
blasts in response to IFNγ[100]. CXCL10 is important for chemo-attraction of mono-
cytes/macrophages, T-cells, NK-cells and dendritic cells to sites of inflammation. Fur-
ther, it promotes T-cell adhesion to endothelial cells and exerts anti-tumor 
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effects[101, 102]. CXCL10 inhibits proliferation of endothelial and epithelial 
cells[103].  
In a recent phase II study MDX-1100, a human monoclonal anti-CXCL10 
antibody, demonstrated clinical efficacy in RA patients who did not respond to meth-
otrexate and revealed an acceptable safety profile[104]. In a placebo-controlled trial 
in patients with moderate to severe UC, MDX-1100 did not show a significant clinical 
benefit when compared to placebo in the overall population[105]. However, when 
data were stratified according to MDX-1100 trough serum levels, there were increas-
ing rates for response, remission and mucosal healing with increasing MDX serum 
levels. Unfortunately, also the rates for infections and serious infections increased by 
increasing MDX serum concentrations. Currently, phase II trials in patients with UC 
and CD are ongoing.  
 
 
Human recombinant IL-10 
IL-10 is produced by T-cells, B-cells, macrophages/monocytes activated 
and dendritic cells. It inhibits cytokine production by Th1-cells when they are activat-
ed under conditions requiring the presence of antigen presenting cells. IL-10 strongly 
reduced antigen specific human T-cell proliferation by diminishing the antigen pre-
senting capacity of monocytes via down-regulation of class II MHC expression. In 
addition, it inhibits cytokine production by activated macrophages, e. g. LPS-induced 
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expression of IL-1α, IL-6, or TNF. It thus plays not only a role in the regulation of T-
cell activation, but also in the down-regulation of acute inflammatory respons-
es[106]. 
 
Recent interest in IBD research has focused on the anti-inflammatory 
properties of IL-10. The important role of IL-10 for immune homeostasis in the gut 
has been demonstrated by IL-10 deficient mice, which develop chronic entero-colitis 
which can be prevented by administration of IL-10. The down-regulation of IBD 
mononuclear phagocyte activation by IL-10 in vitro has recently been demonstrated 
and recent study linked variation within the gene, encoding the IL-10 receptor with 
increased susceptibility for IBD[107, 108, 109]. In animal experiments, IL-10 admin-
istration was able to prevent colitis, but was ineffective to attenuate already estab-
lished colitis[110, 111]. Interestingly, adenoviral vector-based strategies of IL-10 
gene transfer have been shown to improve symptoms of colitis and RA in respective 
animal models[6, 112, 113, 114, 115, 116, 117].   
 
The anti-inflammatory effect of IL-10 on mucosal inflammation has been 
found in vivo when patients with ulcerative colitis received IL-10 enema treatment. 
Patients with steroid refractory ulcerative colitis treated with IL-10 enemas showed a 
progressive down-regulation of peripheral monocyte pro-inflammatory cytokine se-
cretion and a clinical improvement[118, 119]. Additionally, in a first trial in patients 
with steroid-refractory CD, 50% of patients receiving recombinant IL-10 subcutane-
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ously achieved remission compared to 23% of patients in the placebo group [119]. 
However, in large trials assessing the effect of recombinant IL-10 in patients with 
mild to moderate CD, no significant advantage in achieving clinical remission in re-
sponse to subcutaneous, recombinant IL-10 was noted in 329 steroid-refractory pa-
tients when compared to placebo, while therapy was well tolerated in general[120, 
121]. Recombinant IL-10 also was not sufficient to prevent the recurrence of inflam-
mation in CD patients who had undergone ileal or ileocolonic resection[122]. The 
disappointing observations could have a number of possible explanations: the admin-
istered dose of IL-10 may have been too low (however it is limited by side effects) 
and/or the application form was ineffective (subcutaneous administration with only 
little of IL-10 reaching sites of active inflammation), IL-10 might only be sufficient for 
preventing, but not for improving active inflammation (as suggested by the animal 
experiments), administration of IL-10 alone is not sufficient to block the expression 
of all of the important, pro-inflammatory mediators and the immuno-stimulatory ef-
fects of IL-10, in particular on B-cells and on IFNγ production, may abrogate its anti-
inflammatory effects[123].  
 
To address these issues, several methods have been developed. One 
method was to design genetically engineered Lactococcus lactis bacteria that can be 
administered orally and transport the IL-10 directly to the sites of inflammation. 
Though this approach seems to be safe, it finally failed to show clinical activity in 
phase II studies[124]. A further approach might be the rectal application of gelatine 
 31 
microspheres containing interleukin-10, which has been shown to be effective in 
mouse models[125]. Gene therapy using replication-deficient adenoviral vectors to 
deliver the IL-10 gene directly to gastrointestinal epithelial cells also has been sug-
gested. Such a route of administration has already been shown to be effective in a 
murine model of RA[126]. 
 
 
Human recombinant IL-11 
Similar to IL-10, IL-11, a cytokine mainly produced by bone marrow 
stromal and other mesenchymal cells, also exerts anti-inflammatory effects in the in-
testine[127]. IL-11 modulates Th1/Th2-type cytokine production from activated T-
cells and protects the intestinal mucosa[128, 129, 130]. Further, IL-11 is able to im-
pair the lipopolysaccharide-induce secretion of pro-inflammatory mediators from 
macrophages/monocytes[131]. A polymorphism within the IL-11 gene is associated 
with increased susceptibility for UC[132].  
In early trials, subcutaneously administered IL-11 appeared to be safe 
and efficient in about one third of CD patients[133, 134]. However, in a further trial, 
IL-11 was significantly inferior when compared to prednisolone with respect to re-
sponse rate and rate of short-term remission in 51 patients with active CD[135].   
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Human recombinant IFNβ 
A further approach using recombinant biologics molecules for treating 
IBD is the administration of the type I interferon, IFNβ. These cytokine are widely 
expressed and play a crucial role for innate anti-viral immune responses, but have al-
so a critical effect in the modulation of the anti-inflammatory host response[136]. In 
mouse models of arthritis, IFNβ exerts anti-inflammatory properties by suppressing 
the secretion of pro-inflammatory cytokines and chemokines, such as TNF, IFNγ, IL-
6, IL-12 or CXCL8 and by stimulating the secretion of the anti-inflammatory IL-
10[137, 138, 139, 140]. 
In a first study, where it was also administered subcutaneously, IFNβ 
showed a very promising remission rate for about 88% with a mean remission length 
of about 13 months in patients with steroid-refractory UC[141]. Subsequent random-
ized, placebo-controlled studies also suggested that IFNβ could exert some beneficial 
effects in UC patients, however the results were clearly not as good as in the initial 
trial[61, 142, 143]. Nevertheless, some studies even suggested that IFNβ does not 
have superior therapeutic effect in UC patients when compared to placebo[144, 145]. 
Of note, the remission rates of IFNβ were always higher when compared to placebo. 
However, sometimes these differences were not statistically significant.  
In a recent study in patients with CD there was also no significant effect 
in favor of IFNβ when compared to placebo[146]. Further data suggest that the anti-
inflammatory effect of IFNβ is due to the inhibition of IL-13 production[61]. Though 
in all of the conducted trials, IFNβ revealed to be safe and well tolerable there are 
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recent case reports that IFNβ treatment in patients with multiple sclerosis was asso-
ciated with development of IBD[147]. Recent data suggested that IFNγ administra-
tion exacerbated colitis in a mouse model of colitis[148]. While the data of the two 
most recent trials using IFNβ in patients with UC have not been published to date, 
their results will be of great interest.  
 
 
 
New biologicals directed against cytokine receptors 
Besides the inhibition of cytokines by antibodies the targeting and inhibi-
tion of the respective cytokine receptor represents an additional mechanism how cy-
tokine-induced signaling and consecutive effects can be blocked efficiently. With re-
spect to IBD, inhibition of the receptors for IL-2, IL-6, IL-17 and IL-21 as well as of 
the chemokine (C-C motif) ligand 25 (CCL25), namely C-C chemokine receptor type 
9, has gained interest. 
 
Anti-IL-2-receptor (IL-2R) strategies 
IL-2 is a pleiotropic cytokine that is produced by T-cells upon antigen-
binding to the T-cell receptor (TCR) and plays an important role in the differentiation 
and proliferation of naive T-cells into effector T-cells. Activation of TCR results in se-
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cretion of IL-2 and the expression of the IL-2R on the surface of the T-cells[149, 
150]. The interaction between IL-2 and the IL-2R finally stimulates growth, differen-
tiation and survival of antigen-specific CD4+ and CD8+ cells[151]. IL-2 hereby is cru-
cial for the development of memory T-cells (that display the immunologic memory of 
the body) as well as for the maturation and differentiation of regulatory T-cells 
(Tregs). Tregs prevent autoimmune diseases by preventing other T-cells from recog-
nizing and reacting against self-antigens which means that IL-2 is required to dis-
criminate between self and non-self[152, 153, 154]. Of note, recombinant IL-2 is ap-
proved for the treatment of malignant melanoma and renal cell cancer.  
 
Basiliximab 
Recent studies suggest that the use of anti-IL-2R treatment could be 
beneficial in the therapy of UC. In initial pilot studies, the anti-IL-2R antibody, basilix-
imab showed clinical efficacy in patients with steroid-resistant UC. Nine out of 10 pa-
tients achieved clinical remission at week 8. However, 8 out of these 9 patients re-
lapsed, but remission could be re-achieved by administration of corticosteroids and 
azathioprine. After 24 weeks, 7 patients were in full remission and, in the presence 
of basiliximab, patients became again sensitive to steroids[155]. In a further open-
label trial, steroid-resistant UC patients were treated with a single dose of basiliximab 
in combination with steroids. Here, 65% of the patients achieved clinical remission at 
week 24[156]. In general, basiliximab treatment was well tolerated. However, a very 
recent, placebo-controlled study including 149 patients with moderate to severe UC 
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demonstrated that basiliximab does not increase efficacy of corticosteroids in pa-
tients with steroid-refractory UC. The remission rates in the basiliximab groups were 
even slightly lower than those in the placebo group[157].  
 
Daclizumab 
A further anti-IL-2R antibody, namely daclizumab[158], revealed also 
some clinical benefit in a pilot study in patients with refractory UC. However, in a 
subsequent, larger, randomized trial including 159 patients with moderate UC, treat-
ment with daclizumab did not result in increased rates of clinical remission at week 8 
compared to placebo[159]. Similar to basiliximab, daclizumab was also well tolerated. 
 
 
Anti-IL-6-receptor (IL-6R) strategies 
Tocilizumab 
Anti-IL-6 antibodies seem to be a reasonable approach for the treatment 
of IBD (see above). A further possibility to inhibit IL-6 mediated effects is the block-
ade of the IL-6R. Tocilizumab is a monoclonal anti-IL-6R antibody that is already ap-
proved as second line therapy for the treatment of RA. To date, only the data from 
one placebo-controlled phase I trial in 36 patients with active CD are available. Here, 
80% of the CD patients treated with tocilizumab showed a clinical response com-
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pared with 31% of patients in the placebo group. Only 20% of the tocilizumab-
treated patients went finally in remission[160]. Adverse events were comparable in 
the tocilizumab and placebo group. Data from RA patients suggest that tocilizumab 
treatment increases the incidence of grade III neutropenia, infections, abnormal liver 
function and elevated lipids. Though these adverse events are generally mild and are 
resolved upon treatment, especially the long-term effects of the latter two observa-
tions have to be further explored[161, 162]. A further anti-IL-6R antibody, namely 
sarilumab, is currently in phase II and III studies in patients with RA and ankylosing 
spondylitis.  
 
Anti-IL-17-rerceptor (IL-17R) strategies 
Though results for inhibition of IL-17 were not convincing, inhibiting the 
IL-17R has been considered to be a worthwhile approach for IBD treatment. In ex-
ample, brodalumab, a human anti-IL-17R monoclonal antibody, has been shown to 
improve moderate-to-severe plaque psoriasis in a large, randomized and placebo-
controlled phase II study[163]. 
 
Anti-IL-21-receptor (IL-21R) strategies 
IL-21 is also a member of the IL-17 cytokine family and exerts potent 
regulatory effects on immune cells, including NK-cells and cytotoxic T-cells. IL-21 in-
duces cell division and proliferation in its target cells[164, 165]. Further, IL-21 is ex-
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pressed in NK-cells and activated CD4+ T-cells and IL-21 expression is up-regulated 
in Th2 and Th17 cells as well as T follicular cells[166, 167, 168]. In particular, ATR-
107 (PF05230900) is an IL-21R antagonist that is currently tested in phase I studies. 
 
 
Anti-C-C chemokine receptor type 9 (CCR9) 
CCR9 is the receptor for CCL25 and seems to play a pivotal role for leu-
kocyte homing to the gut mucosa. While CCR9 is expressed on T-cells and plasmacy-
toid dendritic cells, it ligand can only be detected in the small intestine, but neither in 
the caecum nor the colon. CCR9 is important for the attraction of these cells to the 
lamina propria. In contrast, homing of CD4+ T-cells to the lamina propria of the small 
intestine seems to be less dependent on CCR9[169, 170, 171, 172]. In a mouse 
model of colitis, the sites of inflammation coincide with the with the location of 
CCL25 expression and the number of CCR9+ T-cells increases with disease progres-
sion reaching a peak at the time point when most severe inflammation can be ob-
served[173]. However, in this model of inflammation, blockade of either CCL25 or 
CCR9 was only effective in early stages of the disease development[174]. In a fur-
ther colitis mouse model, deficiency of CCL25 or CCR9 did not have any effect on 
disease development or progression[175]. However, it has also recently been 
demonstrated that CCL25-CCR9 signaling is important for the migration of Tregs into 
the intestinal mucosa and administration of a CCL9-antibody exacerbated inflamma-
tion in a mouse model of ileitis[176]. 
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CCX282-B 
 CCX282-B is a small molecule inhibitor of CCR9 that blocks migration of 
gut-specific T-cells[177]. In a recent, double-blind and placebo-controlled phase II 
study in patients with moderated to severe CD, CCX282-B was well tolerated and 
safe, since no drug related adverse events, particularly no serious or opportunistic in-
fections, were detected during the 36-week maintenance study period. Though there 
was no significant difference in achieving clinical response at week 8, the primary 
end-point of the study, there was a significant difference in achieving clinical re-
sponse at week 12 between patients receiving CCX282-B and placebo. The trial also 
revealed that following the induction of remission by CCX282-B, in about 50% of the 
patients remission was maintained at week 36, while in placebo-treated patients, re-
mission rates continuously declined. Further, a smaller number of patients treated 
with CCX282-B needed steroid rescue therapy when compared to the placebo group. 
Currently, the effect of CCX282-B is studied in phase III trials in CD patients. 
 
 
New drugs directed against cytokine signal transduction 
Besides targeting the cytokine or a cytokine receptor directly, a third ap-
proach to prevent or inhibit cytokine-mediated inflammation is to inhibit the cytokine-
receptor associated signaling pathways. This way, cytokine-induced signaling is inter-
 39 
rupted and the respective effects are prevented. An important signaling intermediate 
of a large number of cytokine receptors are the member of the Janus kinase family 
(JAK) 1, 2 and 3. These JAK-molecules play a crucial role in cytokine-mediated cell 
growth, survival, development and differentiation of immune cells. While JAK1 and 
JAK3 are expressed in a variety of cell types, JAK3 is restricted to hematopoietic 
cells. Further, JAK3 is involved in the signaling pathways induce by IL-2, IL-4, IL-7, 
IL-9, IL-15 and IL-21[178].  
 
Tofacitinib is a first-in-class small-molecule JAK3 inhibitor. Its efficiency is 
currently investigated in a broad range of inflammatory disorders, such as CD, UC or 
RA[179]. In in vitro studies, tofacitinib has been demonstrated to prevent pathologic 
immune phenomena by blocking the production of IL-17, IL-22 and IL-23R effective-
ly. Further, tofacitinib impairs the activation of STAT1 and T-bet transcription factor 
what finally suppresses the differentiation of Th1, Th2 and Th17 cells[180]. In a clin-
ical phase II trial including 139 patients with moderate to severe CD that were ran-
domized to receive one of three doses of tofacitinib or placebo, the primary end 
point, clinical response at week 4, was not achieved. However, there was a signifi-
cant reduction in serum CRP levels and fecal calprotectin levels in patients receiving 
the highest dose of tofacitinib and the drug was in general well tolerated [181]. In a 
phase II trial including 194 patients with moderate to severe UC, that were random-
ized to receive one of four doses of tofacitinib or placebo, tofacitinib reached its pri-
mary endpoint, which was clinical response at week 8. The clinical response rates in 
the patient groups receiving the two highest tofacitinib doses were 61%-78% com-
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pared to 42% in the placebo group. Clinical remission rates at week 8 were 41% and 
49%, respectively, for the patient groups receiving the highest tofacitinib doses 
(10% in the placebo group). In general, tofacitinib was well tolerated[182]. These 
observations strongly indicate the plausibility of further studies using tofacitinib in 
IBD patients. 
 
 
Summary and outlook 
In the last few years, a large number of new approaches targeting cyto-
kines and chemokines for treating IBD patients have been developed. However, only 
a small number of them seem to be really promising for daily clinical practice. In par-
ticular ustekinumab, an antibody directed against the IL-12/IL-23 axis generated 
very promising results in clinical trials and will most likely be approved for the treat-
ment of CD patients soon. In addition, new anti-TNF approaches, antibodies against 
IL-6 or IL-6R as well as tofacitinib, a small molecule inhibitor of the cytokine signal 
transmitter Jak3, seem to be very promising approaches for the treatment of IBD pa-
tients and are likely to be the next series of medications being approved for this 
complex disease. A number of further anti-cytokine antibodies are currently in early 
phase clinical trials and their efficacy in IBD patients has still to be determined (Fig-
ure 2). Considering all of the new anti-cytokine approaches, it looks like treatment 
options for IBD patients, and in particular for such patients that are non-responding 
to currently established treatments, will be essentially improved in the near future. 
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However, the efficacy and safety of all of these new medications in uncontrolled pa-
tient populations and their use in daily clinical practice has still to be determined. 
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Figure legends 
 
Figure 1. Cytokines and cytokine-associated molecules as current drug targets for 
the treatment of IBD. The image shows the targets as well as the pharmaceutical 
agents for treatment of IBD that are currently studied in clinical trials in IBD patients  
 
 
Figure 2. The pipeline of anti-cytokine medications for the treatment of IBD.  
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Tables 
Agent Company Target Indication Trials Phase Other indications 
TNF-Kinoid Neovacs TNF CD ongoing 3  
DLX105 Delenex TNF CD ongoing 2 Osteoarthritis II 
Golimumab Johnson and 
Johnson 
TNF UC ongoing 3  
C326 QPharm IL-6  CD ongoing 1  
PF 04236921 Pfizer IL-6  CD ongoing 2  
BMS945429 BMS IL-6  CD ongoing 2  
Ustekinumab Centocor IL-12/23 CD ongoing 3  
AMG139 Amgen IL-23 CD ongoing 1  
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QAX576 Novartis IL-13  CD ongoing 2  
Anrukinzumab Pfizer IL-13  UC ongoing 2  
Tralokinumab Astra Zeneca IL-13  UC ongoing 2  
Vidofludimus 4SC AG IL-17A+F CD+UC ongoing 2  
MDX-1100 Medarex CXCL10 
(IP-10) 
CD, UC ongoing 2  
IFNβ recom-
binant 
 IFNβ UC, CD ongoing 3  
Tocilizumab Roche IL-6R CD ongoing 1  
CCX282-B GSK CCR9 CD ongoing 3  
Tofacitinib Pfizer Jak-3 CD, UC ongoing 2  
Briakinumab Abbott IL-12/23  CD failed 2  
Apilimod me-
sylate 
Synta Phar-
maceuticals 
IL-12/23  CD failed  2  
Secukinumab  Novartis IL-17A  CD failed 2  
IL-10 recom-
binant 
Schering-
Plough 
IL-10 CD failed   
IL-11 recom-
binant 
 IL-11 CD failed   
Daclizumab Facet Bio-
tech 
IL-2R UC failed   
Basiliximab Cerimon 
Pharmaceu-
ticals 
IL-2R UC failed   
Ozoralizumab Pfizer TNF  no IBD trials 2 RA II 
Sirukumab GSK IL-6  - no IBD trials - RA, phase III 
Olokizumab  UCB IL-6 - no IBD trials - RA II 
SCH900222 Merck & Co IL-23   no IBD trials 1-2 Psoriasis 
Lebrikizumab Roche IL-13  - no IBD trials - Asthma 
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Ixekizumab Eli-Lilly IL-17A  - no IBD trials - Psoriasis, phase III 
RG4934 Roche IL-17A  - no IBD trials - Psoriasis, phase II 
GSK 1070806 GSK IL-18  - no IBD trials - Healthy and obese 
subjects, phase I 
Canakinumab Novartis IL-1β  - no IBD trials - Approved, acute 
gout 
XOMA 052 XOMA IL-1β - no IBD trials - RA, phase II 
Fezakinumab Pfizer IL-22  - no IBD trials - RA, phase II 
Reslizumab Cephalon IL-5 - no IBD trials - Asthma, phase III 
Mepolizumab GSK IL-5 - no IBD trials - Asthma, phase III 
Sarilumab Sanofi IL-6R - no IBD trials - RA, phase II 
Brodalumab  Amgen IL-17R  - no IBD trials - Psoriasis, phase II 
PF 05230900 Pfizer IL-21R - no IBD trials - Phase I 
 
 
Table 1: The therapeutic pipeline in IBD. 
